https://www.prnewswire.com/news-releases/pionyr-immunotherapeutics-completes-62-million-series-b-financing-to-advance-antibody-based-therapeutics-targeting-the-tumor-microenvironment-300570304.html#new_tab2018-05-23T18:25:26+00:00https://www.homologymedicines.com/news-story/homology-medicines-announces-closing-of-initial-public-offering#new_tab2018-05-23T18:30:29+00:00http://allogene.com/docs/Project%20Carthage%20Press%20Release%20-%20FINAL%20040218.pdf#new_tab2018-05-23T18:27:02+00:00https://www.businesswire.com/news/home/20180403005767/en/Vida-Ventures-Unveils-Next-Generation-Life-Sciences-Venture#new_tab2018-05-23T18:28:55+00:00https://endpts.com/the-under-40s-how-does-the-next-generation-of-biopharma-executives-view-the-future/#new_tab2018-05-23T18:30:04+00:00https://www.prnewswire.com/news-releases/homology-medicines-presents-data-from-pku-gene-therapy-program-demonstrating-long-term-durability-of-treatment-in-ind-enabling-studies-300650829.html2018-06-01T13:42:42+00:00https://www.businesswire.com/news/home/20180523005294/en/Kronos-Bio-Appoints-Dr.-Norbert-Bischofberger-Head#new_tab2018-06-04T18:20:36+00:00http://www.ey.com/Publication/vwLUAssets/Greater_Los_Angeles_2018_Master_Entrepreneur_Announced/$FILE/EOYGLAMasterEntrepreneurAward2018-ArieBelldegrun.pdf#new_tab2018-06-14T19:26:47+00:00https://www.prnewswire.com/news-releases/sutro-biopharma-announces-85-4-million-series-e-round-300687201.html#new_tab2020-04-15T17:22:47+00:00https://www.sutrobio.com/sutro-biopharma-announces-85-0-million-initial-public-offering/#new_tab2019-02-19T21:31:08+00:00https://www.businesswire.com/news/home/20181002005362/en/FierceBiotech-Names-Kronos-Bio-%E2%80%9CFierce-15%E2%80%9D-Biotech#new_tab2019-02-19T21:30:49+00:00https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-announces-pricing-initial-public-offering#new_tab2019-02-19T21:31:37+00:00https://www.businesswire.com/news/home/20190201005241/en/TPG-Capital-Lani-Fritts-Partner-Launch-Kadiant#new_tab2019-02-19T21:32:00+00:00https://www.businesswire.com/news/home/20190220005028/en/Peloton-Therapeutics-Secures-150-Million-Series-Financing#new_tab2020-04-15T17:22:28+00:00https://www.businesswire.com/news/home/20190226005311/en/Oyster-Point-Raises-93-Million-Support-Clinical2020-04-15T17:22:22+00:00https://www.businesswire.com/news/home/20190411005352/en/AskBio-Partners-TPG-Vida-Ventures2020-04-15T17:22:14+00:00https://www.businesswire.com/news/home/20190521005432/en/Merck-Acquire-Peloton-Therapeutics-Bolstering-Oncology-Pipeline2020-04-15T17:22:07+00:00https://www.businesswire.com/news/home/20190718005176/en/Vida-Ventures-Co-Leads-105-Million-Series-Financing#new_tab2020-04-15T17:22:01+00:00https://www.businesswire.com/news/home/20190801005310/en/Vida-Ventures-Closes-600-Million-Vida-II2020-04-16T18:51:44+00:00https://www.businesswire.com/news/home/20191008005307/en/Vida-Ventures-Appoints-New-Chief-Financial-Operating#new_tab2020-04-15T17:21:45+00:00https://www.businesswire.com/news/home/20191219005150/en/Kinnate-Biopharma-Closes-74.5M-Series-Financing#new_tab2020-04-16T18:50:48+00:00https://www.prnewswire.com/news-releases/pact-pharma-raises-75m-in-oversubscribed-series-c-financing-to-develop-fully-personalized-neotcr-t-cell-therapies-for-patients-with-cancer-300985029.html?tc=eml_cleartime#new_tab2020-04-23T18:33:11+00:00https://www.prnewswire.com/news-releases/kyverna-therapeutics-secures-25-million-series-a-funding-from-key-investors-and-enters-into-strategic-collaboration-with-gilead-sciences-300985379.html#new_tab2020-04-23T18:32:56+00:00https://www.businesswire.com/news/home/20200326005123/en/%C2%A0ReCode-Therapeutics-Raises-80-Million-Oversubscribed-Series#new_tab2020-04-23T18:32:43+00:00https://www.businesswire.com/news/home/20200504005051/en/Praxis-Precision-Medicines-Launches-100-Million-Advance#new_tab2020-05-04T15:04:53+00:00https://www.dyne-tx.com/dyne-therapeutics-announces-115-million-financing-to-advance-pipeline-of-modern-oligonucleotide-therapeutics-for-serious-muscle-diseases/#new_tab2020-08-10T15:32:35+00:00https://praxismedicines.com/2020/07/28/praxis-precision-medicines-announces-110-million-financing/#new_tab2020-08-10T20:02:54+00:00https://bwnews.pr/2Ysr5RF2020-09-14T18:38:28+00:00https://www.businesswire.com/news/home/20200826005301/en/Kinnate-Biopharma-Closes-98-Million-Series-Financing#new_tab2020-08-26T11:53:24+00:00https://www.businesswire.com/news/home/20200914005309/en/Neogene-Therapeutics-Raises-110-Million-Series-A-Financing-to-Develop-Next-Generation-Fully-Personalized-Neo-Antigen-T-Cell-Receptor-TCR-Therapies#new_tab2020-09-15T15:22:57+00:00https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-pricing-initial-public-offering#new_tab2020-09-29T15:29:37+00:00https://www.a2bio.com/copy-of-press-release-11-05-19#new_tab2020-10-06T12:40:56+00:00https://www.neogene.com/neogene-therapeutics-appoints-former-roche-chairman-and-chief-executive-officer-franz-b-humer-ph-d-as-executive-chairman-of-board-of-directors/#new_tab2020-10-09T15:09:04+00:00https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-pricing-initial-public-offering#new_tab2020-10-09T15:49:52+00:00https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-closing-initial-public-offering#new_tab2020-10-26T16:25:25+00:00https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-closing-initial-public-offering-and-full#new_tab2020-10-26T16:24:41+00:00https://www.globenewswire.com/news-release/2020/10/16/2109633/0/en/Praxis-Precision-Medicines-Announces-Pricing-of-Upsized-Initial-Public-Offering.html#new_tab2020-10-26T16:24:02+00:00https://www.businesswire.com/news/home/20201026005156/en/Scorpion-Therapeutics-Launches-with-108-Million-to-Advance-Precision-Oncology-2.0#new_tab2021-01-06T16:20:00+00:00https://media.bayer.de/baynews/baynews.nsf/id/Bayer-acquires-Asklepios-BioPharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy#new_tab2020-10-26T16:23:16+00:00https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-closing-initial-public#new_tab2020-10-26T16:56:51+00:00https://www.businesswire.com/news/home/20201029005454/en/LianBio-Announces-310-Million-Crossover-Financing#new_tab2020-10-29T15:14:58+00:00https://www.prnewswire.com/news-releases/pionyr-immunotherapeutics-initiates-phase-1-clinical-study-of-py314-301175564.html#new_tab2020-11-19T22:25:53+00:00https://www.businesswire.com/news/home/20201119005290/en/Pfizer-and-LianBio-Announce-Strategic-Collaboration-to-Expand-Development-of-Novel-Therapeutics-in-Greater-China#new_tab2020-11-19T22:26:36+00:00https://www.precisionmedicinegrp.com/2020/11/precision-medicine-group-secures-major-investment-from-blackstone/#new_tab2021-01-06T16:19:27+00:00https://www.globenewswire.com/news-release/2020/12/03/2138755/0/en/Kinnate-Biopharma-Announces-Pricing-of-Initial-Public-Offering.html#new_tab2020-12-04T10:44:09+00:00https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-announces-closing-initial-public-offering-and#new_tab2021-01-06T16:18:55+00:00https://www.globenewswire.com/news-release/2020/12/14/2144195/0/en/InnoSkel-Launches-with-20-Million-Series-A-Financing.html#new_tab2021-01-06T16:18:30+00:00https://www.prnewswire.com/news-releases/locanabio-announces-100-million-series-b-financing-to-advance-portfolio-of-novel-rna-targeted-gene-therapies-for-neurodegenerative-neuromuscular-and-retinal-diseases-301191356.html#new_tab2020-12-14T14:47:24+00:00https://www.prnewswire.com/news-releases/a2-biotherapeutics-enters-into-collaboration-agreement-with-merck-to-develop-allogeneic-cell-therapy-for-solid-tumor-cancers-301197998.html#new_tab2020-12-23T15:26:40+00:00https://www.businesswire.com/news/home/20210105005224/en/IconOVir-Bio-Raises-77-Million-in-Series-A-Financing-to-Develop-Next-Generation-Oncolytic-Viruses-to-Treat-Solid-Tumors#new_tab2021-01-06T16:17:46+00:00https://www.businesswire.com/news/home/20210107005191/en/Scorpion-Therapeutics-Announces-Oversubscribed-162-Million-Series-B-Financing#new_tab2021-01-07T15:30:47+00:00https://www.businesswire.com/news/home/20210216005355/en/Centessa-Pharmaceuticals-Launches-with-250-Million-Series-A-Financing-and-Unveils-a-New-Kind-of-Pharmaceutical-RD-Model#new_tab2021-02-16T20:06:32+00:00https://www.prnewswire.com/news-releases/aktis-oncology-announces-72m-series-a-financing-to-advance-breakthrough-radiopharmaceuticals-to-treat-solid-tumors-301249763.html#new_tab2021-03-18T14:55:17+00:00https://www.businesswire.com/news/home/20210415005211/en/Tectonic-Therapeutic-Launches-with-80-Million-Series-A-Financing-to-Transform-the-Discovery-of-Novel-G-Protein-Coupled-Receptor-GPCR--Targeted-Therapies#new_tab2021-04-15T13:26:25+00:00https://www.businesswire.com/news/home/20210510005205/en/Centessa-Pharmaceuticals-Appoints-One-of-the-World%E2%80%99s-Leading-Drug-Developers-Antoine-Yver-M.D.-M.Sc.-as-Chief-Medical-Officer#new_tab2021-05-10T15:24:29+00:00https://investors.centessa.com/news-releases/news-release-details/centessa-announces-closing-initial-public-offering-and-full#new_tab2021-06-21T19:38:04+00:00https://www.businesswire.com/news/home/20210624005358/en/Vida-Ventures-Closes-825-Million-Vida-III-Fund-to-Advance-Transformative-Biomedical-Innovations#new_tab2021-06-24T10:24:52+00:00https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-positive-topline-data-proof#new_tab2021-09-09T14:57:30+00:00https://www.businesswire.com/news/home/20210818005173/en/Vigil-Neuroscience-Completes-90-million-Series-B-Financing-to-Advance-a-Pipeline-of-Microglia-targeted-Medicines-to-Treat-Rare-and-Common-Neurodegenerative-Diseases#new_tab2021-09-09T15:00:01+00:00https://recodetx.com/recode-therapeutics-raises-oversubscribed-series-b-financing-round-of-80-million/#new_tab2021-10-28T19:26:17+00:00https://www.globenewswire.com/news-release/2021/10/26/2320578/0/en/Quanta-Therapeutics-Announces-Oversubscribed-60-Million-Series-C-Financing-to-Advance-Novel-RAS-targeting-Programs.html#new_tab2021-10-28T19:29:23+00:00https://www.globenewswire.com/news-release/2021/11/17/2336493/0/en/Protego-Biopharma-Raises-51-Million-Series-A-Financing-to-Advance-the-Treatment-of-Protein-Misfolding-Diseases.html#new_tab2021-11-17T17:20:25+00:00https://innovativegenomics.org/news/women-in-enterprising-science-program/2022-03-01T21:12:30+00:00https://endpts.com/the-endpoints-11-the-top-private-biotechs-in-pursuit-of-new-drugs-pushing-the-envelope-with-powerful-new-technologies/2022-09-22T16:39:30+00:00https://www.globenewswire.com/en/news-release/2022/01/11/2365242/0/en/Vigil-Neuroscience-Announces-Closing-of-Initial-Public-Offering.html2022-09-24T21:15:36+00:00https://www.scorpiontx.com/press-release/scorpion-therapeutics-enters-agreement-with-astrazeneca-to-discover-develop-and-commercialize-novel-cancer-treatments-against-undruggable-targets/2022-09-24T21:17:13+00:00https://www.biospace.com/article/releases/alterome-therapeutics-launches-with-64m-series-a-financing/?s=802022-09-24T21:17:58+00:00https://www.volastratx.com/volastra-therapeutics-announces-drug-discovery-collaboration-with-bristol-myers-squibb/2022-09-24T21:19:28+00:00https://affinittx.com/placeholder-text-for-press-release-announcement/2022-09-24T21:20:31+00:00https://www.fiercepharma.com/pharma/most-influential-people-biopharma-serial-entrepreneurs2022-09-24T21:22:47+00:00https://affinittx.com/affini-t-therapeutics-metagenomi-announce-next-generation-gene-editing-partnership-to-advance-cell-therapies-for-solid-tumor-patients/2022-09-24T21:23:42+00:00https://www.businesswire.com/news/home/20220629005119/en/ReCode-Therapeutics-to-Expand-Next-Generation-Delivery-Platform-and-Diversify-Genetic-Medicines-Pipeline-with-Oversubscribed-Series-B-Financing-Totaling-200M2022-09-24T21:34:27+00:00http://fiercebiotech.com/special-reports/fierce-biotechs-2022-fierce-15#vidaportfolio2022-09-24T21:36:48+00:00https://www.businesswire.com/news/home/20220914005134/en/Capstan-Therapeutics-Launches-with-165-Million-to-Deliver-on-the-Clinical-Promise-of-Precise-In-Vivo-Cell-Engineering2022-09-24T21:37:32+00:00https://www.neogene.com/astrazeneca-to-acquire-neogene-therapeutics-accelerating-ambition-in-oncology-cell-therapy/#new_tab2022-12-01T19:49:21+00:00https://www.businesswire.com/news/home/20230105005243/en/Affini-T-Therapeutics-to-Present-at-the-41st-Annual-J.P.-Morgan-Healthcare-Conference2023-01-05T18:25:28+00:00https://kyvernatx.com/press-releases/kyverna-therapeutics-announces-first-patient-enrolled-in-phase-1-clinical-trial-of-cd19-car-t-cell-therapy-for-lupus-nephritis-in-the-u-s/2023-06-30T18:56:39+00:00https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-announces-dosing-first-subject2023-07-10T14:36:41+00:00https://www.businesswire.com/news/home/20230711691585/en/IconOVir-Bio-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-its-Lead-Product-Candidate-ICVB-1042?utm_campaign=shareaholic&utm_medium=linkedin&utm_source=socialnetwork2023-07-15T00:42:16+00:00https://kyvernatx.com/press-releases/kyverna-therapeutics-extends-series-b-financing-round-to-145-million-and-brings-in-new-investors/2023-08-03T18:36:16+00:00https://www.avalynpharma.com/avalyn-raises-175-million-in-oversubscribed-series-c-financing-to-advance-inhaled-pulmonary-fibrosis-programs-into-later-stage-clinical-studies/2023-09-27T21:03:28+00:00https://www.scorpiontx.com/press-release/scorpion-therapeutics-and-pierre-fabre-laboratories-announce-first-patient-dosed-in-phase-1-2-clinical-trial-of-stx-721-a-mutant-selective-egfr-exon-20-inhibitor-for-thetreatment-of-locally-advanced/2023-10-12T03:59:55+00:00https://www.quantatx.com/news/10-11-23/2023-10-12T04:02:22+00:00https://www.scorpiontx.com/press-release/scorpion-therapeutics-presents-preclinical-data-for-stx-241-a-fourth-generation-egfr-inhibitor-at-the-aacr-nci-eortc-symposium-2023/2023-10-13T21:31:44+00:00https://www.globenewswire.com/news-release/2023/10/17/2761374/0/en/Vigil-Neuroscience-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-in-Healthy-Volunteers-Evaluating-VG-3927-a-Small-Molecule-TREM2-Agonist-for-Potential-Treatment-of-Al.html2023-10-17T17:25:18+00:00https://www.businesswire.com/news/home/20231024942608/en/Scorpion-Therapeutics-Appoints-Precision-Medicine-Leader-Jeff-Albers-as-Strategic-Advisor2023-10-24T13:31:50+00:00https://www.volastratx.com/volastra-therapeutics-announces-first-patient-dosed-in-phase-i-ii-clinical-trial-of-vls-1488-one-in-a-portfolio-of-novel-and-differentiated-kif18a-inhibitors/2023-10-30T15:38:41+00:00https://affinittx.com/press-releases/affini-t-therapeutics-to-present-preclinical-gene-editing-data-from-its-program-targeting-kras-g12d-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting/2023-11-01T23:02:53+00:00https://www.avalynpharma.com/avalyn-presents-data-from-its-ap01-and-ap02-inhaled-therapeutics-programs-for-pulmonary-fibrosis/2023-11-10T01:11:24+00:00https://affinittx.com/press-releases/affini-t-therapeutics-appoints-healthcare-capital-markets-veteran-kathy-bergsteinsson-mba-as-chief-financial-officer/2023-11-13T18:37:16+00:00https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-publication-in-the-lancet-neurology-of-case-report-of-patient-with-refractory-myasthenia-gravis-treated-with-investigational-kyv-101-301989844.html?tc=eml_cleartime2023-11-18T17:02:01+00:00https://tectonictx.com/wp-content/uploads/2023/11/news_2023-11-28_Tectonic-Therapeutic-Announces-Start-of-First-Clinical-Program-for-GPCR-Targeted-Biologic.pdf2023-11-28T18:17:29+00:00https://recodetx.com/recode-therapeutics-doses-first-patient-in-phase-1-clinical-study-of-novel-mrna-based-therapy-for-the-treatment-of-primary-ciliary-dyskinesia/2024-01-05T00:42:13+00:00https://www.prnewswire.com/news-releases/aktis-oncology-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302025043.html2024-01-05T00:44:30+00:00https://www.biospace.com/article/nextgen-class-of-2024-top-life-sciences-startups-to-watch-this-year/2024-01-05T00:45:50+00:00https://www.prnewswire.com/news-releases/kyvernas-kyv-101-receives-us-fda-clearance-for-treatment-of-patients-with-refractory-progressive-multiple-sclerosis-in-the-kysa-7-phase-2-trial-302025646.html?tc=eml_cleartime2024-01-05T00:46:27+00:00https://www.businesswire.com/news/home/20240130047688/en/AVROBIO-and-Tectonic-Therapeutic-Announce-Merger2024-01-30T16:06:34+00:00https://www.prnewswire.com/news-releases/kyverna-therapeutics-granted-fda-fast-track-designation-for-kyv-101-in-the-treatment-of-patients-with-refractory-myasthenia-gravis-302014277.html2024-02-10T01:06:56+00:00https://www.prnewswire.com/news-releases/kyverna-therapeutics-announces-pricing-of-upsized-initial-public-offering-302056924.html2024-02-10T01:41:07+00:00https://recodetx.com/intellia-therapeutics-and-recode-therapeutics-announce-strategic-collaboration-to-develop-novel-gene-editing-therapies-for-cystic-fibrosis/2024-02-16T00:58:23+00:00https://recodetx.com/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-study-of-inhaled-mrna-based-genetic-medicine-rct2100-for-the-treatment-of-cystic-fibrosis/2024-02-21T18:39:12+00:00https://www.capstantx.com/posts/capstan-therapeutics-announces-175m-oversubscribed-series-b-financing/2024-03-20T14:07:21+00:00https://www.businesswire.com/news/home/20240325487405/en/Tectonic-Therapeutic-Initiates-Phase-1B-Study-for-TX45-in-Group-2-Pulmonary-Hypertension-in-Patients-with-Preserved-Ejection-Fraction-Heart-Failure2024-03-26T17:39:10+00:00https://www.businesswire.com/news/home/20240403342221/en/Alterome-Therapeutics-Raises-132-Million-in-Series-B-Financing-Led-by-Goldman-Sachs-Alternatives2024-04-09T18:14:21+00:00https://www.businesswire.com/news/home/20240620882931/en/Tectonic-Therapeutic-Announces-Closing-of-Merger-with-AVROBIO-as-well-as-Concurrent-Private-Placement-of-130.7-Million2024-08-13T18:33:58+00:00https://www.prnewswire.com/news-releases/indupro-announces-85-million-series-a-financing-appoints-prakash-raman-phd-as-ceo-to-advance-next-generation-proximity-based-protein-therapeutics-for-the-treatment-of-cancer-and-autoimmune-diseases-302171386.html2024-08-13T18:34:13+00:00https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-announces-40-million-strategic-investment2024-08-13T18:33:35+00:00https://www.scorpiontx.com/press-release/scorpion-therapeutics-announces-150-million-series-c-financing/2024-08-13T18:39:52+00:00https://www.prnewswire.com/news-releases/third-arc-bio-launches-with-oversubscribed-165-million-series-a-financing-to-deliver-superior-biologics-for-solid-tumors-and-inflammatory--immunology-ii-diseases-302201952.html2024-08-13T18:32:59+00:00https://www.businesswire.com/news/home/20240812060613/en/Halda-Therapeutics-Secures-126-Million-Financing-to-Advance-RIPTAC%E2%84%A2-Cancer-Therapies-into-the-Clinic-for-Major-Solid-Tumors2024-08-13T18:32:37+00:00https://www.aktisoncology.com/news/aktis-oncology-enters-into-strategic-collaboration-with-lilly-to-discover-and-develop-novel-anticancer-radiopharmaceuticals/2024-08-13T18:34:38+00:00https://www.businesswire.com/news/home/20240909342829/en/Candid-Therapeutics-Debuts-with-370M-Capital-Raise-to-Clinically-Evaluate-Potentially-Transformative-Autoimmune-Therapies2024-09-09T18:06:08+00:00https://recodetx.com/recode-therapeutics-doses-first-patient-in-phase-1b-clinical-study-of-rct2100-for-the-treatment-of-cystic-fibrosis/2024-09-26T23:26:51+00:00https://haldatx.com/halda-therapeutics-appoints-veteran-biopharma-leader-christian-schade-as-president-and-chief-executive-officer/2024-10-01T16:44:36+00:00https://www.prnewswire.com/apac/news-releases/precision-medicine-group-welcomes-margaret-keegan-as-ceo-302264010.html#:~:text=About%20Margaret%20Keegan%2C%20CEO%20of,and%20leading%20life%20sciences%20companies.2024-10-01T17:08:29+00:00https://www.linkedin.com/posts/vida-ventures-llc_we-are-deeply-saddened-by-the-passing-of-activity-7273116556128075776-5Iyn?utm_source=share&utm_medium=member_desktop2024-12-12T23:41:11+00:00https://www.globenewswire.com/news-release/2025/01/08/3006104/0/en/LB-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Trial-of-LB-102-in-Schizophrenia.html2025-01-09T22:51:35+00:00https://www.prnewswire.com/news-releases/lilly-to-acquire-scorpion-therapeutics-mutant-selective-pi3k-inhibitor-program-302349242.html2025-01-13T15:35:00+00:00https://investors.tectonictx.com/news-releases/news-release-details/tectonic-therapeutic-announces-positive-interim-data-phase-1b2025-01-30T16:00:59+00:00https://www.businesswire.com/news/home/20250224162426/en/Halda-Therapeutics-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Trial-Evaluating-HLD-0915-in-Metastatic-Castration-Resistant-Prostate-Cancer2025-02-24T15:30:26+00:00https://www.businesswire.com/news/home/20250401919724/en/Vida-Ventures-Taps-Industry-Heavyweights-from-JP-Morgan-and-MPM-BioImpact-to-Further-Power-Leadership-Team2025-04-02T11:29:53+00:00https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-enters-definitive-merger-agreement-be2025-05-23T20:36:20+00:00https://www.aktisoncology.com/news/aktis-initiates-clinical-trial-of-potential-nectin-4-targeting-radiopharmaceutical-product-candidate/2025-05-28T16:20:01+00:00https://antaresrx.com/2025-06-10T17:33:31+00:00https://www.capstantx.com/press-releases/capstan-therapeutics-announces-initiation-of-phase-1-trial-of-lead-in-vivo-car-t-therapy-cptx2309-for-treating-autoimmune-disease/?category=all2025-06-11T21:07:51+00:00https://www.capstantx.com/press-releases/abbvie-to-acquire-capstan-therapeutics-further-strengthening-commitment-to-transforming-patient-care-in-immunology/2025-06-30T13:22:20+00:00https://www.globenewswire.com/news-release/2025/09/11/3148301/0/en/LB-Pharmaceuticals-Announces-Pricing-of-its-Upsized-Initial-Public-Offering.html2025-09-11T16:32:28+00:00https://endpoints.news/endpoints-11-winner-2025-third-arcs-talented-team-goes-after-big-targets/2025-09-22T16:23:29+00:00https://www.businesswire.com/news/home/20250919018956/en/Candid-Therapeutics-Recognized-as-a-2025-Endpoints-11-Honoree2025-09-24T20:29:12+00:00https://www.businesswire.com/news/home/20250929553112/en/ReCode-Therapeutics-Announces-Over-%2429-Million-in-Additional-Financing-to-Advance-Genetic-Medicines-Pipeline-and-Provides-Corporate-Update2025-09-29T20:47:36+00:00https://www.protegobio.com/press-release/2025-12-01T22:55:29+00:00https://haldatx.com/halda-therapeutics-announces-acquisition-by-johnson-johnson/2025-12-01T22:59:09+00:00https://webreprints.djreprints.com/2624814.html2025-12-01T23:16:39+00:00https://www.businesswire.com/news/home/20260109857776/en/Vida-Ventures-Congratulates-Aktis-Oncology-on-Its-Entry-into-the-Public-Markets2026-01-09T18:18:27+00:00https://www.businesswire.com/news/home/20260107745236/en/Poplar-Therapeutics-Launches-With-%2450M-Series-A-to-Advance-a-New-Class-of-Anti-IgE-Therapy-for-Multiple-Atopic-Conditions2026-01-21T00:43:29+00:00https://adcendo.com/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/2026-04-14T17:35:38+00:00https://www.businesswire.com/news/home/20260503600344/en/Two-River-and-Vida-Ventures-Extend-Track-Record-of-Company-Creation-and-Value-Realization-Following-the-Candid-Therapeutics-Acquisition-by-UCB2026-05-06T19:23:20+00:00https://investors.avalynpharma.com/news-releases/news-release-details/avalyn-announces-closing-initial-public-offering-and-full2026-05-04T00:10:09+00:00https://www.ucb.com/newsroom/press-releases/article/ucb-to-acquire-candid-therapeutics-building-upon-its-existing-immunology-pipeline-with-novel-t-cell-engagers2026-05-06T17:10:26+00:00https://www.businesswire.com/news/home/20260610731032/en/SonoThera-Closes-Oversubscribed-%24125-Million-Series-B-Financing-to-Advance-Clinical-Development-of-Ultrasound-Mediated-Nonviral-Genetic-Medicines2026-06-10T20:34:30+00:00